| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
13.00(B) |
| Last
Volume: |
1,143,139 |
Avg
Vol: |
421,691 |
| 52
Week Range: |
$210.76 - $276.5 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
576,795 |
633,480 |
690,363 |
1,841,548 |
| Total Sell Value |
$141,127,434 |
$154,067,329 |
$166,940,864 |
$453,181,711 |
| Total People Sold |
8 |
8 |
8 |
10 |
| Total Sell Transactions |
72 |
83 |
94 |
262 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-05-26 |
4 |
OE |
$53.42 |
$160,260 |
D/D |
3,000 |
3,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-05-25 |
4 |
AS |
$218.50 |
$670,731 |
D/D |
(3,000) |
130 |
|
-7% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-05-25 |
4 |
OE |
$53.42 |
$160,260 |
D/D |
3,000 |
3,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-05-24 |
4 |
AS |
$210.03 |
$649,609 |
D/D |
(3,000) |
130 |
|
-2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-05-24 |
4 |
OE |
$53.42 |
$160,260 |
D/D |
3,000 |
3,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-05-23 |
4 |
AS |
$200.06 |
$628,829 |
D/D |
(3,000) |
130 |
|
2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-05-23 |
4 |
OE |
$53.42 |
$160,260 |
D/D |
3,000 |
3,130 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-05-19 |
4 |
AS |
$183.06 |
$1,100,593 |
D/D |
(6,000) |
36,397 |
|
12% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-05-19 |
4 |
OE |
$111.00 |
$666,000 |
D/D |
6,000 |
42,397 |
|
- |
|
| Patusky Christopher |
|
– • – |
2022-05-17 |
4 |
D |
$190.99 |
$381,980 |
D/D |
(2,000) |
1,680 |
|
- |
|
| Patusky Christopher |
|
– • – |
2022-05-17 |
4 |
OE |
$63.90 |
$127,800 |
D/D |
2,000 |
3,680 |
|
- |
|
| Dwek Raymond |
|
– • – |
2022-04-28 |
4 |
D |
$179.34 |
$358,680 |
D/D |
(2,000) |
0 |
|
- |
|
| Dwek Raymond |
|
– • – |
2022-04-28 |
4 |
OE |
$48.11 |
$96,220 |
D/D |
2,000 |
2,000 |
|
- |
|
| Dwek Raymond |
|
– • – |
2022-04-21 |
4 |
D |
$190.22 |
$380,440 |
D/D |
(2,000) |
0 |
|
- |
|
| Dwek Raymond |
|
– • – |
2022-04-21 |
4 |
OE |
$48.11 |
$96,220 |
D/D |
2,000 |
2,000 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-04-21 |
4 |
AS |
$187.20 |
$1,135,078 |
D/D |
(6,000) |
36,397 |
|
19% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-04-21 |
4 |
OE |
$111.00 |
$666,000 |
D/D |
6,000 |
42,487 |
|
- |
|
| Dwek Raymond |
|
– • – |
2022-04-07 |
4 |
D |
$190.11 |
$380,220 |
D/D |
(2,000) |
0 |
|
- |
|
| Dwek Raymond |
|
– • – |
2022-04-07 |
4 |
OE |
$48.11 |
$96,220 |
D/D |
2,000 |
2,000 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-04-07 |
4 |
AS |
$184.93 |
$1,113,095 |
D/D |
(6,000) |
36,487 |
|
18% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-04-07 |
4 |
OE |
$111.00 |
$666,000 |
D/D |
6,000 |
42,487 |
|
- |
|
| Patusky Christopher |
|
– • – |
2022-04-07 |
4 |
D |
$190.11 |
$380,220 |
D/D |
(2,000) |
1,680 |
|
- |
|
| Patusky Christopher |
|
– • – |
2022-04-07 |
4 |
OE |
$63.90 |
$127,800 |
D/D |
2,000 |
3,680 |
|
- |
|
| Thompson Tommy G |
|
– • – |
2022-03-29 |
4 |
D |
$178.46 |
$267,690 |
D/D |
(1,500) |
6,520 |
|
- |
|
| Thompson Tommy G |
|
– • – |
2022-03-29 |
4 |
OE |
$48.11 |
$72,165 |
D/D |
1,500 |
8,020 |
|
- |
|
5060 Records found
|
|
Page 26 of 203 |
|
|
4.68 (1.73%) 
